ARCT - Arcturus Therapeutics Holdings Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures4

Market Cap (intraday) 812.30M
Enterprise Value 515.17M
Trailing P/E 87.37
Forward P/E 2.48
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)4.03
Price/Book (mrq)3.01
Enterprise Value/Revenue 1.84
Enterprise Value/EBITDA 4.38

Trading Information

Stock Price History

Beta (5Y Monthly) 2.61
52-Week Change 336.67%
S&P500 52-Week Change 31.77%
52 Week High 333.80
52 Week Low 311.70
50-Day Moving Average 325.23
200-Day Moving Average 319.26

Share Statistics

Avg Vol (3 month) 3521.71k
Avg Vol (10 day) 3386.44k
Shares Outstanding 526.56M
Implied Shares Outstanding 6N/A
Float 822.93M
% Held by Insiders 113.83%
% Held by Institutions 181.50%
Shares Short (May 14, 2023) 43.32M
Short Ratio (May 14, 2023) 47
Short % of Float (May 14, 2023) 416.72%
Short % of Shares Outstanding (May 14, 2023) 412.50%
Shares Short (prior month Apr 13, 2023) 42.81M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Nov 15, 2017
Ex-Dividend Date 4N/A
Last Split Factor 21:7
Last Split Date 3Nov 15, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Mar 30, 2023


Profit Margin 39.59%
Operating Margin (ttm)27.51%

Management Effectiveness

Return on Assets (ttm)11.89%
Return on Equity (ttm)43.30%

Income Statement

Revenue (ttm)281.04M
Revenue Per Share (ttm)10.61
Quarterly Revenue Growth (yoy)1,431.00%
Gross Profit (ttm)62.95M
Net Income Avi to Common (ttm)111.27M
Diluted EPS (ttm)3.98
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)327.94M
Total Cash Per Share (mrq)12.35
Total Debt (mrq)33.17M
Total Debt/Equity (mrq)10.08
Current Ratio (mrq)4.71
Book Value Per Share (mrq)12.40

Cash Flow Statement

Operating Cash Flow (ttm)45.16M
Levered Free Cash Flow (ttm)-11.12M